NewGenIvf's Notification from Nasdaq
BANGKOK — NewGenIvf Group Limited (NASDAQ: NIVF) has recently received important communication from the Nasdaq Stock Market LLC. A letter from the Listing Qualifications Department informed the company that it is currently not meeting the minimum bid price requirement set forth under Nasdaq Listing Rule 5450(a)(1).
Understanding the Deficiency Letter
This notification, referred to as the 'Deficiency Letter', stated that NewGenIvf's Class A Ordinary Shares have not met the minimum closing bid price of $1 per share for the past 30 consecutive business days. NewGenivf is provided a specific timeline—a compliance period of 180 calendar days from the date of the letter—to address this issue and regain compliance before the stipulated Compliance Date.
Compliance Timeline Explained
NewGenIvf must demonstrate a closing bid price of at least $1 for a minimum of ten consecutive business days. If successful, Nasdaq will confirm that the company is back in compliance with its listing requirements. As of now, the deadline set for compliance is approaching rapidly, creating a crucial timeframe for the company to strategize and implement solutions.
Possible Consequences of Non-Compliance
If NewGenivf fails to meet these requirements by the Compliance Date, the company could face notification regarding the potential delisting of its securities from Nasdaq. However, NewGenivf has the option to request additional time for compliance by notifying Nasdaq of its intent to rectify the deficiency.
Proactive Steps Toward Compliance
In response to this situation, NewGenivf plans to actively monitor the bid price of its Class A Shares. Additionally, the management is considering appropriate actions to foster compliance with Nasdaq’s guidelines. This could include strategic initiatives aimed at increasing the visibility and market presence of their stock.
Continued Trading on Nasdaq
Despite receiving the Deficiency Letter, it is important to note that there is no immediate impact on the trading of NewGenivf’s Class A Shares. The shares will continue to trade on Nasdaq under the ticker symbol “NIVF”, providing investors with the opportunity to remain engaged with the company’s performance.
About NewGenIvf
NewGen is a notable player in the fertility services sector in Asia, dedicated to providing accessible fertility treatments to couples and individuals. The company aims to support family-building journeys, regardless of fertility challenges faced by their clients. NewGenIvf has established clinics across Thailand, Cambodia, and Kyrgyzstan, offering a broad range of services, including infertility treatments and assisted reproductive technologies.
Services Offered by NewGen
The services include egg and sperm donation, surrogacy options, and comprehensive infertility treatments designed to cater to the unique needs of patients. With an experienced management team that has over a decade of industry knowledge, NewGenivf is committed to pioneering fertility solutions and expanding their services in their respective markets.
Investor Relations and Support
For those invested in NewGenivf's journey and compliance efforts, the investor relations team stands ready to provide updates. The company’s representatives are accessible for inquiries and to offer any necessary information to stakeholders.
Frequently Asked Questions
What does the Deficiency Letter from Nasdaq entail?
The Deficiency Letter indicates that NewGenIvf's shares have not maintained the minimum bid price of $1, requiring the company to take action to regain compliance.
How long does NewGenIvf have to address the compliance issue?
The company has a 180-day period to meet the minimum bid price requirement, with a Compliance Date set for the near future.
What steps can NewGenIvf take to regain compliance?
NewGenIvf plans to monitor its share price actively and may explore strategies to enhance its stock market performance and visibility.
Will the shares continue to be traded on Nasdaq?
Yes, the company’s Class A Shares will continue trading under the ticker symbol “NIVF” despite the compliance notification.
What are the implications of not regaining compliance?
If compliance is not achieved by the deadline, NewGenIvf risks receiving notification of potential delisting from Nasdaq.
